Vaccibody Gets Funding to Develop Vaccine

Therapeutic vaccine company Vaccibody has received a 2 million euro ($2.5 million) grant from the Norwegian Research Council's BIA Program to develop a therapeutic vaccine against precancerous lesions of the cervix. The company is also working with the National Hospital, Norway, and with the EU project ADITEC to assess a preventive influenza vaccine in a protein format.

North AmericaUSBriefs